Project Grant R15CA309873
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $566K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arlington, TX 76019, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $623,432 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on May 7, 2026, with a completion date of April 30, 2031. This award supports the development and refinement of the Cancer Vision Goggle (CVG), a head-mounted fluorescence-guided surgery (FGS) system designed to improve surgical outcomes in cancer procedures by...
- Federal Project Grant Award Summary The University of Texas at Austin received a $668,878 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 3, 2026, with completion scheduled for March 31, 2031. This award funds the development of a novel antibody-drug conjugate (ADC)-based therapeutic platform targeting CD44 variant 9 (CD44V9) to treat aggressive and treatment-resistant breast cancer, particularly triple-negative and...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on mechanistic characterization of benzothiazepinone inhibition of NVL (Norovirus-Like), an essential AAA+ adenosine triphosphatase (ATPase) enzyme involved in ribosomal large subunit (60S)...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute awarded UT Southwestern Medical Center a $683,885 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. This project develops the first clinical prototype for Proton Minibeam Radiation Therapy (PMBRT), an advanced spatially fractionated radiation therapy modality designed to improve cancer treatment outcomes by delivering highly modulated spatial dose patterns that enhance...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Michigan Technological University a $1.15 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 20, 2025, for a three-year research initiative extending through July 31, 2028. The award supports development of ratiometric near-infrared (NIR) fluorescent probes utilizing BODIPY dyes to detect viscosity changes and protein aggregation in live cells. These self-calibrating probes will...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the five-year period from June 1, 2026 through May 31, 2031. This award funds the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research utilizes an integrated platform combining high-throughput phenotypic screening with...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $663,818 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective May 1, 2026 through April 30, 2031. This award supports a longitudinal research initiative assessing the impact of early physiotherapy intervention on breast cancer-related lymphedema (BCRL) and lymphatic dysfunction in breast cancer survivors. The project employs...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.46 million Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, with a completion date of July 31, 2030. The INHANCE (Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery) initiative addresses a critical public health need in reducing therapy-related normal tissue injury among head and neck...